Logo

Glenmark to Initiate P-III Clinical Study Evaluating the Combination Therapy for Hospitalized Patients with COVID-19 in India

Share this

Glenmark to Initiate P-III Clinical Study Evaluating the Combination Therapy for Hospitalized Patients with COVID-19 in India

Shots:

  • Glenmark has received the DCGI’s approval to initiate P-III FAITH study assessing Favipiravir + Umifenovir + SOC and Favipiravir + SOC in 158 hospitalized patients with moderate COVID-19. On day 1- patients will receive Faviprivir (1800mg- bid) and Umifenovir (800mg- bid)- followed by 800mg of each for the remaining course of the treatment
  • Treatment duration of the study is 14days and patients will be discharged after clinical cure & two consecutive negative tests for COVID-19 based on RT-PCR. The two antivirals with different MOA complement and enhance efficacy against COVID-19
  • Additionally- Glenmark is evaluating Favipiravir in P-III clinical study as monothx. with 150 patients with COVID-19 with its anticipated results in Jul/ Aug’2020. Glenmark is the first company to receive DCGI’s approval to conduct clinical trials of Favipiravir against COVID-19 in India

Click here to­ read full press release/ article | Ref: Glenmark | Image: Glenmark


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions